Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly
improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF) …

Studies with angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin receptor
blockers (ARBs) in patients with heart failure with preserved ejection fraction (HFpEF) have …

Background: Worsening renal function (WRF) associated with renin-angiotensin-
aldosterone system (RAAS) inhibition does not confer excess risk in heart failure patients …

Aims We investigated the association between worsening renal function (WRF) that occurs
during renin–angiotensin–aldosterone system inhibition initation and outcome in heart …

Aims We evaluated the effect of (dual) renin–angiotensin–aldosterone system (RAAS)
blockade with valsartan and an ACE inhibitor [92.7% of patients were treated with an ACE …

Heart failure with preserved ejection fraction (HF-PEF) is a well-recognized complication of
long-standing hypertension. However, beyond the control of the traditional cardiovascular …

Clinical trials of renin-angiotensin-aldosterone system (RAAS) antagonists in heart failure
with preserved ejection fraction (HFpEF) have suggested neutral results and treatment is …

Background: In patients with heart failure, chronic kidney disease is common and associated
with a higher risk of renal events than in patients without chronic kidney disease. We …

Aims In heart failure (HF) with reduced ejection fraction (EF), renin–angiotensin receptor
(RAS) antagonists reduce mortality. However, severe renal insufficiency was an exclusion …

Aims Patients with heart failure are at higher risk of progression to end‐stage renal disease
(ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin …